A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Sponsor
Zhujiang Hospital
Study ID
NCT06546280
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
  • Apatinib — DRUG
    Apatinib 250 mg will be taken orally once daily.

Study Details

The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.

Key Dates

Start date
Aug 26, 2024
Status verified
Aug 2024
Primary completion
Aug 26, 2026
Completion
Sep 1, 2026

Study Design

Enrollment
38 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group

Primary Outcome Measure

1-year recurrence free survival rate [ Time Frame: Assessed up to 12 months ]

Central Contacts

Related Studies